These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Genome analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki. Taguchi M; Mishima H; Shiozawa Y; Hayashida C; Kinoshita A; Nannya Y; Makishima H; Horai M; Matsuo M; Sato S; Itonaga H; Kato T; Taniguchi H; Imanishi D; Imaizumi Y; Hata T; Takenaka M; Moriuchi Y; Shiraishi Y; Miyano S; Ogawa S; Yoshiura KI; Miyazaki Y Haematologica; 2020; 105(2):358-365. PubMed ID: 31101757 [TBL] [Abstract][Full Text] [Related]
3. Clinical features and prognosis of patients with myelodysplastic syndromes who were exposed to atomic bomb radiation in Nagasaki. Matsuo M; Iwanaga M; Kondo H; Soda M; Jo T; Horio K; Takasaki Y; Kawaguchi Y; Tsushima H; Imaizumi Y; Imanishi D; Taguchi J; Sawayama Y; Hata T; Miyazaki Y Cancer Sci; 2016 Oct; 107(10):1484-1491. PubMed ID: 27487572 [TBL] [Abstract][Full Text] [Related]
4. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Harada H; Harada Y; Tanaka H; Kimura A; Inaba T Blood; 2003 Jan; 101(2):673-80. PubMed ID: 12393679 [TBL] [Abstract][Full Text] [Related]
5. Chromosomal analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki. Horai M; Satoh S; Matsuo M; Iwanaga M; Horio K; Jo T; Takasaki Y; Kawaguchi Y; Tsushima H; Yoshida S; Taguchi M; Itonaga H; Sawayama Y; Taguchi J; Imaizumi Y; Hata T; Moriuchi Y; Haase D; Yoshiura KI; Miyazaki Y Br J Haematol; 2018 Feb; 180(3):381-390. PubMed ID: 29265181 [TBL] [Abstract][Full Text] [Related]
6. Chromosomal instability in acute myelocytic leukemia and myelodysplastic syndrome patients among atomic bomb survivors. Nakanishi M; Tanaka K; Shintani T; Takahashi T; Kamada N J Radiat Res; 1999 Jun; 40(2):159-67. PubMed ID: 10494147 [TBL] [Abstract][Full Text] [Related]
7. Late effect of atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes. Tsushima H; Iwanaga M; Miyazaki Y Int J Hematol; 2012 Mar; 95(3):232-8. PubMed ID: 22370711 [TBL] [Abstract][Full Text] [Related]
8. High frequency of AML1/RUNX1 point mutations in radiation-associated myelodysplastic syndrome around Semipalatinsk nuclear test site. Zharlyganova D; Harada H; Harada Y; Shinkarev S; Zhumadilov Z; Zhunusova A; Tchaizhunusova NJ; Apsalikov KN; Kemaikin V; Zhumadilov K; Kawano N; Kimura A; Hoshi M J Radiat Res; 2008 Sep; 49(5):549-55. PubMed ID: 18724045 [TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108 [TBL] [Abstract][Full Text] [Related]
10. Reclassification of leukemia among A-bomb survivors in Nagasaki using French-American-British (FAB) classification for acute leukemia. Matsuo T; Tomonaga M; Bennett JM; Kuriyama K; Imanaka F; Kuramoto A; Kamada N; Ichimaru M; Finch SC; Pisciotta AV Jpn J Clin Oncol; 1988 Jun; 18(2):91-6. PubMed ID: 2898029 [TBL] [Abstract][Full Text] [Related]
11. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. Nardi V; Winkfield KM; Ok CY; Niemierko A; Kluk MJ; Attar EC; Garcia-Manero G; Wang SA; Hasserjian RP J Clin Oncol; 2012 Jul; 30(19):2340-7. PubMed ID: 22585703 [TBL] [Abstract][Full Text] [Related]
12. [Epidemiology of leukemia and MDS among atomic bomb survivors in Hiroshima and Nagasaki suggests how abnormal epigenetic regulation contributes to leukemogenesis]. Inaba T Rinsho Ketsueki; 2009 Oct; 50(10):1548-52. PubMed ID: 19915365 [No Abstract] [Full Text] [Related]
13. Lessons from the atomic bomb about secondary MDS. Hata T; Imanishi D; Miyazaki Y Curr Hematol Malig Rep; 2014 Dec; 9(4):407-11. PubMed ID: 25240475 [TBL] [Abstract][Full Text] [Related]
14. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287 [TBL] [Abstract][Full Text] [Related]
16. Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes. Cortes J; O'Brien S; Kantarjian H; Cork A; Stass S; Freireich EJ; Keating M; Pierce S; Estey E Leukemia; 1994 Dec; 8(12):2174-8. PubMed ID: 7808007 [TBL] [Abstract][Full Text] [Related]
17. Impact of Nagasaki atomic bomb exposure on myelodysplastic syndrome patients who are treated with azacitidine. Jo T; Horio K; Shigematsu K Anticancer Res; 2015 May; 35(5):2929-33. PubMed ID: 25964578 [TBL] [Abstract][Full Text] [Related]
18. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome. Harada H; Harada Y Crit Rev Eukaryot Gene Expr; 2005; 15(3):183-96. PubMed ID: 16390315 [TBL] [Abstract][Full Text] [Related]
19. Pathoanatomical aspects of malignant haematological disorders among Danish patients exposed to thorium dioxide. Visfeldt J; Andersson M APMIS; 1995 Jan; 103(1):29-36. PubMed ID: 7695889 [TBL] [Abstract][Full Text] [Related]